Gilead Sciences sets aside USD 200 million to resolve HIV drug investigation Ruchika Sharma4 March 2025 4:00 PM ISTNew York: Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into its...
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis Ruchika Sharma23 Feb 2025 11:30 AM ISTFoster City: Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment...
Gilead new drug applications for twice-yearly Lenacapavir for HIV Prevention accepted by USFDA under priority review Ruchika Sharma19 Feb 2025 1:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...
Gilead Sciences Seladelpar gets positive CHMP opinion for Primary Biliary Cholangitis Ruchika Sharma15 Dec 2024 12:00 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences ropes in Sanofi official Dietmar Berger as new Chief Medical Officer Ruchika Sharma13 Dec 2024 4:12 PM ISTFoster City: Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical...
Gilead Sciences, Tubulis ink pact to develop ADC candidate for select solid tumor target Ruchika Sharma8 Dec 2024 10:00 AM ISTFoster City: Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to...
Gilead Sciences inks pacts with Dr Reddy's Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir Ruchika Sharma3 Oct 2024 7:15 PM ISTFoster City: Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical...
USFDA grants accelerated approval to Gilead Sciences Livdelzi for Primary Biliary Cholangitis Ruchika Sharma17 Aug 2024 3:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi...
CMO Merdad Parsey to leave Gilead Sciences Ruchika Sharma21 July 2024 10:00 AM ISTFoster City: Gilead Sciences, Inc. has announced that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While...
USFDA approves Biktarvy label update with data for pregnant adults with HIV: Gilead Sciences Ruchika Sharma28 April 2024 11:30 AM ISTFoster City: Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration (FDA) has approved an updated label with additional data...
Gilead Sciences gets exclusive global license to develop, commercialize Xilio tumor-activated IL-12 Ruchika Sharma31 March 2024 10:00 AM ISTXilio will receive $43.5 million in upfront payments, including a cash payment of $30 million and an initial equity investment by Gilead of $13.5...
Gilead Sciences completes acquisition of CymaBay Therapeutics for USD 4.3 billion Ruchika Sharma24 March 2024 11:00 AM ISTAs a result of the completion of the merger, CymaBay has become a wholly owned subsidiary of Gilead.
